PPLPHARMA filed Apr–Jun 2026 on Wed 29 Jul 2026, read on its consolidated figures (the group).

Revenue was ₹2,270 crore, 17% above a year earlier; profit was ₹-69 crore, not comparable with a year earlier.

Over four quarters it kept -3 of every 100 rupees of revenue as profit.

Its borrowings were 67 in every 100 of its equity at 31 Mar 2026.

4 of the 8 conditions that could be measured held; 1 could not be measured from what it has filed.

• Held: revenue over the last four quarters was above the four before.
• Did not hold: profit over the last four quarters was above the four before.
• Did not hold: profit over the last four quarters was above zero.
• Did not hold: the operating margin over the last four quarters held against the four before.
• Not measured: cash from operations was at least 80 in every 100 of profit, latest full year.
• Held: borrowings were no more than equity.
• Did not hold: profit before interest covered interest at least three times.
• Held: promoters had pledged at most 5 in every 100 of their shares.
• Held: promoters' holding did not fall more than one point in a year.

Healthcare, 20 other companies read for this quarter; revenue over four quarters 1% above the four before, against 15% above the four before for the typical company in the group; it kept -3 of every 100 rupees of revenue as profit, the typical company 13.

The group is its industry as NSE lists it today; each company is read on the quarter it had filed by then, and the company is left out of its own group.

At 30 Jun 2026: promoters held 35 in every 100 shares, foreign investors 13 in every 100, Indian institutions 15 in every 100 (mutual funds 13 in every 100).

Promoters had pledged 0 in every 100 of their shares.